Phase 2 study to improve tolerance of chemotherapy involving cetuximab and multidrug FOLFIRI [folinic acid + fluorouracil + irinotecan], with pharmacokinetic and pharmacogenetic studies, in patients with metastatic colorectal cancer

Trial Profile

Phase 2 study to improve tolerance of chemotherapy involving cetuximab and multidrug FOLFIRI [folinic acid + fluorouracil + irinotecan], with pharmacokinetic and pharmacogenetic studies, in patients with metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Cetuximab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic; Proof of concept
  • Most Recent Events

    • 12 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top